Is InspireMD, Inc. (NSPR) a Buy, Sell, or Hold?
InspireMD, Inc.
NASDAQ:NSPR
$0.7151 USD
$0.0 (-0.33%)
- Volume
- 8.89K
- Average Volume
- 323.19K
- Market Capitalization
- $33.49M
- P/E Ratio
- -1.26
- Dividend Yield
- 0.00%
- Price Target
- $4.50
- Year High
- $2.93
- Year Low
- $0.63
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Marvin L. Slosman |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | NSPR |
| CUSIP | 45779A846 |
| CIK | 0001433607 |
| Web | https://www.inspiremd.com |
| Phone | 888 776 6804 |
| Currency | USD |
| Employees | 127 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.07 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.15 |
| Quick Ratio | 4.82 |
| Cash Ratio | 1.20 |
Sales & Book Value
| Annual Sales | $8.98M |
| Price / Sales | 3.09 |
| Cash Flow | -0.55 |
| Price / Cash Flow | -0.83 |
| Price / Book | 1.20 |
Price Target and Rating
| Average Stock Price Forecast | $4.50 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -84.11% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.76 |
| Trailing P/E Ratio | -1.26 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-48.79M |
| Net Margin | -344.13% |
| Pretax Margin | -343.55% |
| Return on Equity | -81.52% |
| Return on Assets | -66.11% |
Financials Score
| AltmanZ Score | -7.41 |
| Piotroski Score | 3.00 |
| Working Capital | 39.15M |
| Total Assets | 56.47M |
| Ebit | -37.14M |
| Market Cap | 33.72M |
| Total Liabilities | 12.85M |
Poll Results
About InspireMD, Inc. (NASDAQ:NSPR) Stock
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to address various vascular and coronary diseases. The company's offerings, distributed through a network of local partners, reach markets across Europe, Latin America, the Middle East, and Asia Pacific. Key products include the CGuard carotid embolic prevention system, specifically designed for carotid artery procedures, and the MGuard Prime embolic protection systems. The MGuard Prime systems are crucial for patients experiencing acute coronary syndromes, notably acute myocardial infarction, and those undergoing saphenous vein graft coronary intervent ... ions or bypass surgery. InspireMD is also developing PVGuard, an innovative solution combining a MicroNet mesh sleeve with a self-expandable stent, aimed at peripheral vascular applications.
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
2026-06-16 13:46:04
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-12 16:05:00
MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six (6) new non-executive employees in the aggregate amount of 91,161 shares of restricted stock (the “Inducement Grants”) outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of June 12, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted under the InspireMD's 2024 Inducement Plan, which is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
2026-06-11 08:00:00
MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval of the CGuard Prime 80 cm stent implant in the second half of this year.
2026-06-08 08:00:00
MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system (“NPS”), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (“TCAR”) procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio.
2026-05-13 21:20:42
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
2026-05-06 16:05:00
MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13th at 4:20 pm Pacific Time (PT). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com.
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
2026-05-04 18:50:20
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
2026-05-04 18:43:23
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
Frequently Asked Questions
-
What is the current InspireMD, Inc. (NSPR) stock price?
-
InspireMD, Inc.(NASDAQ:NSPR) stock price is $0.7151 in the last trading session. During the trading session, NSPR stock reached the peak price of $2.93 while $0.63 was the lowest point it dropped to. The percentage change in NSPR stock occurred in the recent session was --0.33% while the dollar amount for the price change in NSPR stock was -$-0.0.
-
NSPR's industry and sector of operation?
-
The NASDAQ listed NSPR is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of NSPR?
-
Marvin L. Slosman | President, Chief Executive Officer & Director
Pete Ligotti | Executive Vice President & GM of North America
Shane Thomas Gleason | Chief Commercial Officer
Donna DeChant | Vice President of Human Resources & Organizational Development
Michael A. Lawless | CFO, Secretary & Treasurer -
How many employees does NSPR have?
-
Number of NSPR employees currently stands at 127. NSPR operates from 6303 Waterford District Drive, Miami, None 33126, US.
-
Link for NSPR official website?
-
Official Website of NSPR is: https://www.inspiremd.com
-
How do I contact NSPR?
-
NSPR could be contacted at phone #888 776 6804 and can also be accessed through its website. NSPR operates from 6303 Waterford District Drive, Miami, None 33126, US.
-
How many shares of NSPR are traded daily?
-
The average number of NSPR shares traded daily for last 3 months was 323.19K.
-
What is the market cap of NSPR currently?
-
The market value of NSPR currently stands at $33.49M with its latest stock price at $0.7151